alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
OFFICE OF THE ATTORNEY GENERAL OF TEUS AUSTIN

6-C.MMW

--

Eonorable Charles F. Theobald

County Attorney Galveston,Texas

Dear Sir: spinionNO.C-35'9 Re: Constructionof Article 71X, Section 7, Revised Sivll Statutes of Texes, As.to what cbnztitutes ownershI for purposes of teletlon.

we are in receipt 

### or your letter 

### ,orWay 8.1941, in whloh you request the opinion 

### 0r this departmenton the quetition

and. raot you eubmlt in your letter as follows: wApglicqtion

hes.beenmade to the County Commlssloners*

Court or this County to exempt from taxation the propertyoi several~,.purely public “&iirity 'lneti'tutlons which are purchasing their properties,either by a vendor*s lien retainedby the grantor, or by Deed oi Trust exeeutad,or derarred payments,or oontract

### ror a, deed,

. . .? '. Artlels 7150; Revised Civil Statutes,provide8 in p&t as 

### r0li0w8: ~

wThe following property shell be exempt from taxation,to-wit:

"1; Public oharltlea. - All bu$ldin@ belpnging td 

### fnstftutions or purely-9B+l*c@@arity, togetherwlth the lands belonging tO and iY+Wupled by such lnatltutlons not leased or otherwiseused with a view to prorit., unles:,

auoh rents end profits end all mcnegs and credits are appropriatedfionorable Charles EI.

Theobald, Eage 2

by eush instltutisnrsolely to sustain suoh lnat,itUtlOnr,

and for the benefit of the slsk and disabledmembers and their familiesand the burial of the ssme, or for the maintenanceof personswhen unable to providefor themselves, whether such personaare members of &UC??lnstltutlonsor not. An institution of purely public charity under this srtlcle 1s one which dispenses its aid to its members and others in sickness or distress, or at death, without regard to poverty or riches of the recipient,also when the funds, pro,rjerty and aetets of siichlnstitutionsare placed and bound by its laws to relfeve, aid and administer In any wag to the relief of its members when in want, slcknesa end distress,and providehozaea for its helple,ss and dopondent members and to eduoate and maintain the orphans or lta deoearred members or other per8mm.*

In our Opinion Tlo. O-2268 thie departmentruled that for tax purposes the vendee under a sales contract was e~onsldered

the Wvner of the property despite the fact that legal tltlo **bad** been retainedby the vendor to aeoure the psymentk&the “ptirohaee price. We further ruled that if such propertywas belne used by the vendee es a homesteed the same was exempt for tax purposes. A copy df said opinion is enoloaed,?or your information.
Wcbrllsvo ,tho,-me rule or law la appllaable in th:,e

0888.~ It 1s our opinion thatundrr the law the lnatltut$onelo quertlon are oonsideredes the owner of the propertytor tax gurpoees~. Therefore, if suoh lnstitutlcns put their property to suah a use as to bring them within the ex8!aption **etatod** in Artlole 7150, Seotion 7, supra,we belirve such propertywould be exempt from taxation,

we,trust that the roregolng

### ray answers gous inquiry. : Yours.vsry truly
ATTCR?CYGlTE2?AI.

OF TEXA;" By s/ @lly Goldberg

Assistant

BY RWB Chairman
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Page 8994]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3998]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE


Certification of the Attorney General; Williamson County, TX

    In accordance with Section 8 of the Voting Rights Act, 42 U.S.C. 
1973f, I hereby certify that in my judgment the appointment of Federal 
observers is necessary to enforce the guarantees of the Fourteenth and 
Fifteenth Amendments of the Constitution of the United States in 
Williamson County, Texas. This county is included within the scope of 
the determinations of the Attorney General and the Director of the 
Census made under Section 4(b) of the Voting Rights Act, 42 U.S.C. 
1973b(b), and published in the Federal Register on September 23, 1975 
(40 FR 43,746).

    Dated: February 23, 2010.
Eric H. Holder Jr.,
Attorney General of the United States.
[FR Doc. 2010-3998 Filed 2-25-10; 8:45 am]
BILLING CODE 4410-13-P
§ 522.1086 Guaifenesin solution. ( a ) *Specifications.* Each milliliter of solution contains 50 milligrams (mg) of guaifenesin and 50 mg of dextrose.
( b ) *Sponsors.* See Nos. 037990 and 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer 1 milliliter per pound of body weight by rapid intravenous infusion.
( 2 ) *Indications for use.* For use as a skeletal muscle relaxant.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16189, Mar. 25, 2014, as amended at 86 FR 14820, Mar. 19, 2021]
Ammoniacal Etching Plant Data

TTM Technologies, Inc.

North American Division Chippewa Falls Logan San Diego Santa Ana Santa Clara Stafford

234 Cashman Drive 710 North 600 West 5037 Ruffner Street 2630 S. Harbor Blvd 407 Mathew St. 4 Old Monson Road

Chippewa Falls, WI 54729 Logan, UT 84321 San Diego, CA 92111 Santa Ana, CA 92704 Santa Clara, CA 95050 Stafford, CT 06075

Etch Supplier/Recycler Micronutrients Phibro-Tech Phibro-Tech Phibro-Tech Phibro-Tech Micronutrients

Indianapolis, IN Santa Fe Springs, CA Santa Fe Springs, CA Santa Fe Springs, CA Santa Fe Springs, CA Indianapolis, IN

Etchant Used Ultra Etch AC-CU Fine 9 Accu Guard Plus AC-CU Fine 9 Accu Guard Plus Ultra Etch

1. Control of etcher exhaust Automatic Manual Manual Automatic Manual Automatic

2. Condenser in the exhaust pipe? Yes No Yes Yes Yes Yes

3. Frequency of pH probe cleaning/calibration Once/year

4. Acceptable pH control range

8.3-8.6 8.0-8.3 8.0-8.8 7.9-8.3 8.0-8.8 

8.4=Opt

7.8 - 9.0

5. Control range for chlorides 4 - 6 M 5.0M +/- 1.0

5.8 - 7.8 

moles/liter 5.3-6.7 M

5.0-6.0 

oz/gal

5.0-5.8 

Molar

When <+/- 0.1 S.U. Daily (lab) Calibrated as needed. 

About every 6 months

Daily
§ 520.1157 Iodinated casein. ( a ) *Specifications.* Each 1-gram tablet contains 25 milligrams of iodinated casein.
( b ) *Sponsor.* See No. 017762 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* 1 ⁄ 5 to 1 tablet per 10 pounds of body weight (equivalent to 0.5 to 2.5 milligrams of iodinated casein per pound of body weight).
( 2 ) *Indications for use.* For dogs for apparent decreased thyroid activity where the signs are alopecia, scaliness of the skin surface, loss of hair, seborrhea, thickening of the skin, hyperpigmentation, and lethargy.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[49 FR 22469, May 30, 1984, as amended at 78 FR 28822, May 20, 2014]
§ 211.1 Scope. Cross Reference
Link to an amendment published at 89 FR 51769 , June 18, 2024.
( a ) The regulations in this part contain the minimum current good manufacturing practice for preparation of drug products (excluding positron emission tomography drugs) for administration to humans or animals.
( b ) The current good manufacturing practice regulations in this chapter as they pertain to drug products; in parts 600 through 680 of this chapter, as they pertain to drugs that are also biological products for human use; and in part 1271 of this chapter, as they are applicable to drugs that are also human cells, tissues, and cellular and tissue-based products (HCT/Ps) and that are drugs (subject to review under an application submitted under section 505 of the act or under a biological product license application under section 351 of the Public Health Service Act); supplement and do not supersede the regulations in this part unless the regulations explicitly provide otherwise. In the event of a conflict between applicable regulations in this part and in other parts of this chapter, or in parts 600 through 680 of this chapter, or in part 1271 of this chapter, the regulation specifically applicable to the drug product in question shall supersede the more general.
( c ) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this part shall not be enforced for OTC drug products if the products and all their ingredients are ordinarily marketed and consumed as human foods, and which products may also fall within the legal definition of drugs by virtue of their intended use. Therefore, until further notice, regulations under parts 110 and 117 of this chapter, and where applicable, parts 113 through 129 of this chapter, shall be applied in determining whether these OTC drug products that are also foods are manufactured, processed, packed, or held under current good manufacturing practice.
[43 FR 45077, Sept. 29, 1978, as amended at 62 FR 66522, Dec. 19, 1997; 69 FR 29828, May 25, 2004; 74 FR 65431, Dec. 10, 2009; 80 FR 56168, Sept. 17, 2015]
# C_2014194EN.01001201.xml

| 24.6.2014 | EN | Official Journal of the European Union | C 194/12 |
| --- | --- | --- | --- |

24.6.2014

EN

Official Journal of the European Union

C 194/12

---

Request for a preliminary ruling from the Finanzgericht Baden-Württemberg (Germany) lodged on 24 March 2014 — Mineralquelle Zurzach AG v Hauptzollamt Singen

(Case C-139/14)

2014/C 194/14

Language of the case: German

Referring court

Referring court

Finanzgericht Baden-Württemberg

Parties to the main proceedings

Parties to the main proceedings

Applicant: Mineralquelle Zurzach AG

Applicant:

Defendant: Hauptzollamt Singen

Defendant:

Questions referred

Questions referred

| 1. | Is a non-alcoholic beverage that consists mainly of water but also has 12 % fruit juices and contains, in addition to sugar, a vitamin mixture which clearly exceeds the vitamin content, in relation to the proportion of juice, of natural fruit juices, to be classified under subheading 2202 10 00 of the Combined Nomenclature? |
| --- | --- |

1.

Is a non-alcoholic beverage that consists mainly of water but also has 12 % fruit juices and contains, in addition to sugar, a vitamin mixture which clearly exceeds the vitamin content, in relation to the proportion of juice, of natural fruit juices, to be classified under subheading 2202 10 00 of the Combined Nomenclature?

| 2. | If Question 1 is answered in the negative:
  Is such a beverage a fruit juice, diluted with water, under code number 2202 90 10 11 TARIC? |
| --- | --- |

2.

If Question 1 is answered in the negative:

Is such a beverage a fruit juice, diluted with water, under code number 2202 90 10 11 TARIC?

| 3. | If the first two questions are answered in the negative:
  Is such a product to be classified as goods under code number 2202 90 10 10 TARIC? |
| --- | --- |

3.

If the first two questions are answered in the negative:

Is such a product to be classified as goods under code number 2202 90 10 10 TARIC?

---
§ 522.2065 Rabacfosadine. ( a ) *Specifications.* Each vial of powder contains 16.4 milligrams (mg) rabacfosadine. Each milliliter of constituted solution contains 8.2 mg rabacfosadine.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer rabacfosadine at 1 mg/kilogram body weight as a 30-minute intravenous infusion, once every 3 weeks, for up to 5 doses.
( 2 ) *Indications for use.* For the treatment of lymphoma in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[87 FR 10969, Feb. 28, 2022]
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-1998
<PERIOD-START>                             JUL-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                      15,930,242
<SECURITIES>                                         0
<RECEIVABLES>                                  830,533
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            16,760,775
<PP&E>                                       4,573,775
<DEPRECIATION>                               (117,505)
<TOTAL-ASSETS>                              21,217,045
<CURRENT-LIABILITIES>                          177,300
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        51,242
<OTHER-SE>                                  20,988,503
<TOTAL-LIABILITY-AND-EQUITY>                21,217,045
<SALES>                                              0
<TOTAL-REVENUES>                               280,143
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             1,385,595
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (1,105,452)
<INCOME-TAX>                                  (87,000)
<INCOME-CONTINUING>                        (1,018,452)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,018,452)
<EPS-PRIMARY>                                    (.04)
<EPS-DILUTED>                                    (.04)
        

</TABLE>
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7333 Enrolled Bill (ENR)]

        H.R.7333

                     One Hundred Eighteenth Congress

                                 of the

                        United States of America

                          AT THE SECOND SESSION

         Begun and held at the City of Washington on Wednesday,
         the third day of January, two thousand and twenty-four

                                 An Act

 
 To name the Department of Veterans Affairs medical center in West Palm 
      Beach, Florida, as the ``Thomas H. Corey VA Medical Center''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. NAME OF DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER, WEST 
PALM BEACH, FLORIDA.
     The Department of Veterans Affairs medical center in West Palm 
Beach, Florida, shall after the date of the enactment of this Act be 
known and designated as the ``Thomas H. Corey VA Medical Center''. Any 
reference to such medical center in any law, regulation, map, document, 
record, or other paper of the United States shall be considered to be a 
reference to the Thomas H. Corey VA Medical Center.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
```
Exhibit 32



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION
1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



Solely
in connection with the filing of the Annual Report of Retractable Technologies, Inc. (the Company) on Form 10KSB-A2 for the period ended December 31, 2003, as filed with the United States Securities and Exchange Commission on the date
hereof (the Report), the undersigned Thomas J. Shaw, Chief Executive Officer, and Douglas W. Cowan, Chief Financial Officer, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:



(1) The Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2) The information contained in the Report as of the dates and for the periods covered by the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



September 24, 2004



/s/  THOMAS J. SHAWTHOMAS J. SHAWPRESIDENT, CHAIRMAN, ANDCHIEF EXECUTIVE OFFICER/s/  DOUGLAS W. COWANDOUGLAS W. COWANVICE PRESIDENT ANDCHIEF FINANCIAL OFFICER
<PAGE>

                                                         Exhibit 10.14


                         AMENDMENT OF PROMISSORY NOTE


     This Amendment of Promissory Note is made as of July 15, 1996, between
KeraVision, Inc. (the "Company") and Thomas L. Silvestrini (the "Purchaser").

     The Promissory Note ("Note") executed by the Purchaser on July 15, 1994,
under which the Purchaser promised to pay to the Company $17,844.69, plus
interest, on or before July 15, 1996, is hereby amended as follows:

     (1)  The Company and the Purchaser hereby agree that the interest due with
respect to the Note as of the date hereof is $2,064.75, which amount is hereby
added to the original principal amount of the Note, so that the principal as of
the date hereof is $19,909.44.

     (2)  The due date of all principal and interest under the Note is extended
to July 15, 1998.

     (3)  The interest rate of the Note changes as of this Amendment Date from
the original 5.55% per annum, compounded semi-annually, to 5.95% per annum,
compounded semi-annually.


KERAVISION, INC.                        THOMAS A. SILVESTRINI

/s/Mark Fischer-Colbrie                 /s/Thomas A. Silvestrini
____________________________________    _________________________________
Signature                               Signature



By: Mark Fischer-Colbrie
    _________________________________
             Print Name


Title: VP Finance, CFO
      ______________________________

<PAGE>

                         AMENDMENT OF PROMISSORY NOTE


     This Amendment of Promissory Note is made as of July 15, 1996, between
KeraVision, Inc. (the "Company") and Thomas L. Silvestrini (the "Purchaser").

     The Promissory Note ("Note") executed by the Purchaser on July 15, 1994,
under which the Purchaser promised to pay to the Company $27,611.69, plus
interest, on or before July 15, 1996, is hereby amended as follows:

     (1)  The Company and the Purchaser hereby agree that the interest due with
respect to the Note as of the date hereof is $3,194.85, which amount is hereby
added to the original principal amount of the Note, so that the principal as of
the date hereof is $30,806.54.

     (2)  The due date of all principal and interest under the Note is extended
to July 15, 1998.

     (3)  The interest rate of the Note changes as of this Amendment Date from
the original 5.55% per annum, compounded semi-annually, to 5.95% per annum,
compounded semi-annually.


KERAVISION, INC.                        THOMAS A. SILVESTRINI

/s/ Mark Fischer-Colbrie                /s/Thomas A. Silvestrini
____________________________________    _________________________________
Signature                               Signature



By: Mark Fischer-Colbrie
   _________________________________
             Print Name



Title: VP Finance, CFO
      ______________________________
<TABLE> <S> <C>



<PAGE>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the M&F
Worldwide Corp. (formerly Power Control Technologies Inc.) Consolidated Balance
Sheet and Statement of Income and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<CIK> 0000945235
<NAME> M&F WORLDWIDE CORP. (FORMERLY POWER CONTROL TECHNOLOGIES INC.)
<MULTIPLIER> 1,000,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                       10
<ALLOWANCES>                                         0
<INVENTORY>                                         50
<CURRENT-ASSETS>                                    61
<PP&E>                                              28
<DEPRECIATION>                                     (2)
<TOTAL-ASSETS>                                     313
<CURRENT-LIABILITIES>                               23
<BONDS>                                              0
<PREFERRED-MANDATORY>                               20
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                         186
<TOTAL-LIABILITY-AND-EQUITY>                       313
<SALES>                                            100
<TOTAL-REVENUES>                                   100
<CGS>                                               54
<TOTAL-COSTS>                                       54
<OTHER-EXPENSES>                                    14
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   7
<INCOME-PRETAX>                                     26
<INCOME-TAX>                                         3
<INCOME-CONTINUING>                                 23
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                        23
<EPS-PRIMARY>                                     1.01
<EPS-DILUTED>                                     0.96
        





</TABLE>
Summary of Comments
**Subject Number of Comments**  **Number of Commenters** Satellite Accumulation 36 24 Tanks 33 8 Containers 29 15 Waste Min + Recy cling 28 16 Clarify Regulations 27 16 Contingency

Management 23 13
Waste Accum ulation 20 19 Training 19 15 Waste Determinations 17 14 Episodic Generation 15 14 Air Emissions 10 8 Land Disposal Restrictions 10 7
Treatment 10 9 RCRA I dentification 9 9 Recordkeeping 9 8 Transportation 8 7 Emergency

Response 4 2 Waste Consolidation 3 3**Totals 310**
Exhibit 8.1List of Subsidiaries     Protherics PLC acts as the holding company of a group consisting of its directly andindirectly held subsidiaries. Protherics PLC has the following principal subsidiaries:           **% Held** **Status** **Country of Incorporation****Direct Holdings**        Protherics Medicines Development Limited  100  trading England and WalesProtherics Inc.  100  trading U.S.A. (Delaware)Enact Pharma Limited  100  trading England and WalesProteus Biotechnology Limited  100  dormant England and WalesGenethics Limited  76  dormant England and Wales**Indirect Holdings**        Protherics UK Limited  100  trading England and WalesProtherics Australasia Pty Limited  100  trading AustraliaProtherics-Utah, Inc.  100  trading U.S.A. (Tennessee)Protherics Services Pty Limited  100  dormant AustraliaProtherics Salt Lake City, Inc.(formerly MacroMed, Inc.)  100  trading U.S.A. (Utah)Kymed GB Limited  100  dormant England and WalesEnzacta R&D Limited  99.8  dormant England and WalesDe Montfort Biopharma Limited  100  dormant England and WalesEnzacta Limited  99.8  dormant England and WalesTAb (Wales) Limited  100  dormant England and WalesTAb (London) Limited  100  dormant England and WalesPolyclonal Antibodies Limited  100  dormant England and Wales
1